
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
- Address
- Ul. Spartanska 1, 02-637 Warsaw, Poland
Centrum Wsparcia Badań Klinicznych - CWBK (Clinical Trials Support Center) of the National Institute of Geriatrics, Rheumatology and Rehabilitation (NIGRiR) is a site conducting clinical trials in fields such as: rheumatology, immunology, neurology, cardiology, orthopedics, rehabilitation, pulmonology, and dermatology. In our modern center, clinical trials are conducted at the highest standard and with maximum comfort for patients.
CWBK, as a highly specialized unit, conducts clinical trials for patients from all over Poland, with particular attention to those who present diagnostic and therapeutic challenges, for whom participation in clinical trials may be the only chance to improve health, slow disease progression, or achieve remission.
The mission of CWBK’s experienced medical teams – doctors and nurses – is to ensure patients have access to modern forms of treatment, improving their health and quality of life, while maintaining the highest global standards of safety and respect for patient rights. The medical staff at CWBK is supported by a team of qualified administrative professionals experienced in managing medical and laboratory documentation in accordance with Good Clinical Practice (GCP) guidelines.
CWBK is actively involved in scientific and clinical initiatives with national and international research communities, paving the way for new projects, diagnostic methods, and future treatment solutions – namely, personalized medicine. The opportunity for these patients to participate in clinical trials not only opens access to drugs and therapies not financed by the National Health Fund (NFZ) but also reduces the cost of accessing and delivering treatment.
Gallery
About This Site
Centrum Wsparcia Badań Klinicznych - CWBK (Clinical Trials Support Center) of the National Institute of Geriatrics, Rheumatology and Rehabilitation (NIGRiR) is a site conducting clinical trials in fields such as: rheumatology, immunology, neurology, cardiology, orthopedics, rehabilitation, pulmonology, and dermatology. In our modern center, clinical trials are conducted at the highest standard and with maximum comfort for patients.
CWBK, as a highly specialized unit, conducts clinical trials for patients from all over Poland, with particular attention to those who present diagnostic and therapeutic challenges, for whom participation in clinical trials may be the only chance to improve health, slow disease progression, or achieve remission.
The mission of CWBK’s experienced medical teams – doctors and nurses – is to ensure patients have access to modern forms of treatment, improving their health and quality of life, while maintaining the highest global standards of safety and respect for patient rights. The medical staff at CWBK is supported by a team of qualified administrative professionals experienced in managing medical and laboratory documentation in accordance with Good Clinical Practice (GCP) guidelines.
CWBK is actively involved in scientific and clinical initiatives with national and international research communities, paving the way for new projects, diagnostic methods, and future treatment solutions – namely, personalized medicine. The opportunity for these patients to participate in clinical trials not only opens access to drugs and therapies not financed by the National Health Fund (NFZ) but also reduces the cost of accessing and delivering treatment.
Feasibility
task_alt 2 on fileDiseases for which the centre has completed a feasibility questionnaire.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 81 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
- 1Amgen Inc.4active
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.5trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE) | Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 81 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tulisokibart | 4 | Unknown | 2022-04-29 | 2026-05-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
